Anuja N.Mehta Ph.D.

Law Clerk

San Diego + 1.858.703.3130

Dr. Anuja Mehta's practice involves domestic and foreign patent portfolio development, management, and enforcement in various areas of life sciences including molecular and cellular biology, antibody therapeutics, pharmaceuticals, cell therapies, vaccines, and microbial biology.

Anuja advises clients regarding patentability, validity, infringement, and freedom-to-operate issues and performs due diligence evaluations of patent portfolios in connection with venture capital and private equity financings, collaborations, and/or partnering deals.

Her practice also includes various post-grant proceedings before the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO), including inter partes reviews (IPRs).

Her current representative clients include Janssen Biotech, Merck, Epic Sciences, and Bellicum Pharmaceuticals, as well as other start-up companies, established companies, academic institutions, and investment firms.

Prior to joining Jones Day in 2016, Anuja obtained her Ph.D. in molecular and cell biology in the lab of Prof. James E. Haber at Brandeis University. She has authored several peer-reviewed publications and has served in several leadership roles throughout her academic studies.

Experience

  • Merck develops global patent portfolio related to certain antibodies for treatment of cognitive disordersJones Day is representing Merck & Co., Inc. in the development and prosecution of global patent portfolios related to certain antibodies that are being developed for the treatment and prevention of various cognitive disorders.
  • Merck develops global patent portfolio related to certain bispecific antibodiesJones Day is representing Merck & Co., Inc. in the development and prosecution of a global patent portfolio related to certain bispecific antibodies.
  • Bellicum Pharmaceuticals establishes global patent portfolio related to CAR-T and other cellular immunotherapiesJones Day is representing Bellicum Pharmaceuticals, Inc. in the development and prosecution of global patent portfolios related to cellular immuno-oncology (IO) and immunotherapies, including BPX-601 (PSCA CAR-T) and BPX-603 (Her2 CAR-T) clinical candidates utilizing the Bellicum’s proprietary GoCAR™ technology.
  • Celgene acquires Juno Therapeutics for $9 billionOn behalf of Celgene Corporation, Jones Day conducted a large-scale intellectual property due diligence review and evaluation of matters related to its definitive merger agreement and acquisition of Juno Therapeutics for approximately $9 billion, including Juno’s technology related to CAR-T and TCR cellular immunotherapeutics for use in oncology and other indications.
  • AbbVie successfully defends HUMIRA® formulation patent against four IPR petitions filed by CoherusJones Day is serving as lead counsel and successfully defended AbbVie in connection with four (4) separate inter partes review (IPR) petitions brought by Coherus Biosciences, Inc. against U.S. Patent No. 9,085,619, which is related to formulations for AbbVie's antibody adalimumab, marketed as HUMIRA®.
  • NGM establishes global patent portfolio related to novel protein therapiesJones Day represents NGM Biopharmaceuticals, Inc. in the establishment of a global patent portfolio related to novel protein therapies for the treatment of diabetes and other metabolic disorders.
  • Additional Publications

    2017

    Homology Requirements and Competition between Gene Conversion and Break-Induced Replication during Double-Strand Break Repair, Molecular Cell, 65(3):515-526

    2016

    Sgs1 and Mph1 Helicases Enforce the Recombination Execution Checkpoint During DNA Double-Strand Break Repair in Saccharomyces cerevisiae, Genetics, 203(2):667-75

    2014

    Sources of DNA double-strand breaks and models of recombinational DNA repair, Cold Springs Harb Perstect Biol., 7;6(9):a016428

    2010

    Analysis of post-operative changes in serum protein expression profiles from colorectal cancer patients by MALDI-TOF mass spectrometry: a pilot methodological study, World J Surj Oncol., 26;8:33

    2009

    Ferritin accumulation under iron scarcity in Drosophila iron cells, Biochemie, 91(10):1331-4

    2008

    Genetic screening for novel Drosophila mutants with discrepancies in iron metabolism, Bichem Soc Trans, 36(Pt 6):1313-6